A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer

Clinical trial NCT02015416 · COMPLETED

Trial details

NCT number: NCT02015416
Sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Melanoma Ovarian Cancer Sarcoma Non-small Cell Lung Cancer Breast Cancer

Start date: 2013-11-01
Primary completion: 2016-12-01
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.